Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses

As mother to child transmission (MTCT) of HIV plays a major part in the persistence of the HIV/AIDS epidemic and bnAb-based passive and active vaccines are a primary strategy for HIV prevention, research in this field is of great importance. While previous MTCT research has investigated the neutralizing antibody activity of HIV-infected women, this is, to our knowledge, the largest study identifying differences in bnAb specificity of maternal plasma between transmitting and nontransmitting women. ABSTRACT Despite the worldwide availability of antiretroviral therapy (ART), approximately 150,000 pediatric HIV infections continue to occur annually. ART can dramatically reduce HIV mother-to-child transmission (MTCT), but inconsistent drug access and adherence, as well as primary maternal HIV infection during pregnancy and lactation are major barriers to eliminating vertical HIV transmission. Thus, immunologic strategies to prevent MTCT, such as an HIV vaccine, will be required to attain an HIV-free generation. A primary goal of HIV vaccine research has been to elicit broadly neutralizing antibodies (bnAbs) given the ability of passive bnAb immunization to protect against sensitive strains, yet we previously observed that HIV-transmitting mothers have more plasma neutralization breadth than nontransmitting mothers. Additionally, we have identified infant transmitted/founder (T/F) viruses that escape maternal bnAb responses. In this study, we examine a cohort of postpartum HIV-transmitting women with neutralization breadth to determine if certain maternal bnAb specificities drive the selection of infant T/F viruses. Using HIV pseudoviruses that are resistant to neutralizing antibodies targeting common bnAb epitopes, we mapped the plasma bnAb specificities of this cohort. Significantly more transmitting women with plasma bnAb activity had a mappable plasma bnAb specificity (six of seven, or 85.7%) compared to that of nontransmitting women with plasma bnAb activity (7 of 21, or 33.3%, P = 0.029 by 2-sided Fisher exact test). Our study suggests that having multispecific broad activity and/or uncommon epitope-specific bnAbs in plasma may be associated with protection against the vertical HIV transmission in the setting of maternal bnAb responses. IMPORTANCE As mother to child transmission (MTCT) of HIV plays a major part in the persistence of the HIV/AIDS epidemic and bnAb-based passive and active vaccines are a primary strategy for HIV prevention, research in this field is of great importance. While previous MTCT research has investigated the neutralizing antibody activity of HIV-infected women, this is, to our knowledge, the largest study identifying differences in bnAb specificity of maternal plasma between transmitting and nontransmitting women. Here, we show that among HIV-infected women with broad and potent neutralization activity, more postpartum-transmitting women had a mappable plasma broadly neutralizing antibody (bnAb) specificity, compared to that of nontransmitting women, suggesting that the nontransmitting women more often have multispecific bnAb responses or bnAb responses that target uncommon epitopes. Such responses may be required for protection against vertical HIV transmission in the setting of maternal bnAb responses.

[1]  L. White,et al.  Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity , 2021, Cell reports. Medicine.

[2]  N. Haigwood,et al.  Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding , 2021, Journal of virology.

[3]  Rachel L. Spreng,et al.  Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses , 2021, Nature.

[4]  W. Heneine,et al.  Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. , 2021, AIDS.

[5]  F. Gao,et al.  Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers , 2021, PLoS pathogens.

[6]  S. MacCarthy,et al.  HIV Care Experiences During the COVID-19 Pandemic: Mixed-Methods Telephone Interviews with Clinic-Enrolled HIV-Infected Adults in Uganda , 2020, AIDS and Behavior.

[7]  B. Haynes,et al.  Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants , 2020, mBio.

[8]  T. Henrich,et al.  HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility , 2019, Journal of Virology.

[9]  J. Bloom,et al.  An Antigenic Atlas of HIV‐1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes , 2019, Immunity.

[10]  T. Hope,et al.  Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1 , 2019, Journal of Virology.

[11]  James Theiler,et al.  HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design , 2019, Cell host & microbe.

[12]  J. Bloom,et al.  An antigenic atlas of HIV-1 escape from broadly neutralizing antibodies , 2018, bioRxiv.

[13]  Sudhir Kumar,et al.  MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. , 2018, Molecular biology and evolution.

[14]  D. Jamieson,et al.  Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity , 2017, mBio.

[15]  D. Montefiori,et al.  Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma , 2017, bioRxiv.

[16]  Mario Roederer,et al.  Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques , 2017, Science.

[17]  B. Korber,et al.  Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge , 2017, Science Translational Medicine.

[18]  J. Bloom,et al.  Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody. , 2017, Cell host & microbe.

[19]  J. Dorfman,et al.  The HIV-1 transmission bottleneck , 2017, Retrovirology.

[20]  J. Mullins,et al.  Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures , 2017, Retrovirology.

[21]  Lynn Morris,et al.  Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection , 2016, PLoS pathogens.

[22]  J. Overbaugh,et al.  Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk , 2016, mBio.

[23]  H. Liao,et al.  Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1 , 2015, Journal of Virology.

[24]  J. Mascola,et al.  Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection , 2015, Journal of Virology.

[25]  J. Mascola,et al.  Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection , 2015, Journal of Virology.

[26]  T. Kepler,et al.  Restricted isotype, distinct variable gene usage, and high rate of gp120-specificity of HIV-1 Envelope-specific B cells in colostrum compared to those in blood of HIV-1-infected, lactating African women , 2014, Mucosal Immunology.

[27]  Hongmei Gao,et al.  Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. , 2014, Journal of immunological methods.

[28]  Gwo-Yu Chuang,et al.  NEP: web server for epitope prediction based on antibody neutralization of viral strains with diverse sequences , 2014, Nucleic Acids Res..

[29]  B. Korber,et al.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection , 2014, AIDS.

[30]  Raphael Gottardo,et al.  Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2013, Journal of Virology.

[31]  J. Overbaugh,et al.  HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype , 2013, AIDS.

[32]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[33]  D. Montefiori,et al.  Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes. , 2013, AIDS research and human retroviruses.

[34]  G. Learn,et al.  Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants , 2013, Retrovirology.

[35]  Lynn Morris,et al.  Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.

[36]  Rajesh P. Ringe,et al.  Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies. , 2012, Virology.

[37]  Mario Roederer,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[38]  B. Haynes,et al.  HIV-Specific Functional Antibody Responses in Breast Milk Mirror Those in Plasma and Are Primarily Mediated by IgG Antibodies , 2011, Journal of Virology.

[39]  D. Montefiori,et al.  The Genetic Bottleneck in Vertical Transmission of Subtype C HIV-1 Is Not Driven by Selection of Especially Neutralization-Resistant Virus from the Maternal Viral Population , 2011, Journal of Virology.

[40]  C. Blish,et al.  The Breadth and Potency of Passively Acquired Human Immunodeficiency Virus Type 1-Specific Neutralizing Antibodies Do Not Correlate with the Risk of Infant Infection , 2011, Journal of Virology.

[41]  E. Abrams,et al.  HIV: prevention of mother-to-child transmission. , 2011, BMJ clinical evidence.

[42]  G. Learn,et al.  Origin and Evolution of HIV-1 in Breast Milk Determined by Single-Genome Amplification and Sequencing , 2010, Journal of Virology.

[43]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[44]  Michael G Hudgens,et al.  Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. , 2010, The New England journal of medicine.

[45]  J. Mullins,et al.  Restriction of HIV-1 Genotypes in Breast Milk Does Not Account for the Population Transmission Genetic Bottleneck That Occurs following Transmission , 2010, PloS one.

[46]  J. Overbaugh,et al.  Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. , 2010, Virology.

[47]  C. Kankasa,et al.  Restricted Genetic Diversity of HIV-1 Subtype C Envelope Glycoprotein from Perinatally Infected Zambian Infants , 2010, PloS one.

[48]  O. Gascuel,et al.  SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. , 2010, Molecular biology and evolution.

[49]  Lynn Morris,et al.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.

[50]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[51]  John R. Mascola,et al.  Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.

[52]  Xuesong Yu,et al.  Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[53]  J. Mascola,et al.  Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies , 2008, Journal of Virology.

[54]  Lynn Morris,et al.  Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.

[55]  J. Overbaugh,et al.  Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity , 2006, Journal of Virology.

[56]  Karina Yusim,et al.  Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants , 2006, Journal of Virology.

[57]  Barbra A. Richardson,et al.  Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant , 2006, Journal of Virology.

[58]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[59]  Charles Wood,et al.  Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. , 2002, AIDS research and human retroviruses.

[60]  S. Plaeger,et al.  Perinatal Transmission of Major, Minor, and Multiple Maternal Human Immunodeficiency Virus Type 1 Variants In Utero and Intrapartum , 2001, Journal of Virology.

[61]  C. Chappey,et al.  Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission , 1995, Journal of virology.

[62]  E. Halapi,et al.  Neutralizing antibodies and viral characteristics in mother‐to‐child transmission of HIV‐1 , 1993, AIDS.

[63]  B. Korber,et al.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. , 1992, Science.

[64]  A. B. Wout,et al.  HIV-1 TRANSMISSION , 2000 .

[65]  J. Kreiss,et al.  Mother-to-child transmission of human immunodeficiency virus type 1. , 1996, Epidemiologic reviews.